I want information on..
The newest women who have set up photo blogs in our network. Join today and share your story!
View all Women's Hair Loss Blogs
You are here: Home » News & Research » Hair Loss News Center » Update: Bristol Myers Hair Loss Trial
Update on the new hair loss growth stimulant trial by Bristol Myers
The conductors of the study claimed that it was 1,000 times more potent than Minoxidil however, and showed good results in animal models.
Recently, Dr. Proctor of www.drproctor.com did some research and notified us of a couple patents owned by Bristol Myers which seem to fit the description almost perfectly. Up to this point even the research centers gathering participants were not given any information as to the specifics on the compound, however having contacted the San Diego chapter, we did get verification that this does indeed sound like the compound being used. Below is the patent information:
The (R)-enantiomer of 4-[[(cyanoimino)[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile as well as the corresponding (S)-enantiomer are useful for promoting hair growth such as in male pattern baldness.
Inventors: Atwal; Karnail S. (Newtown, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Appl. No.: 119884
Filed: July 21, 1998
BACKGROUND OF THE INVENTION
Potassium channel openers such as minoxidil (Upjohn), pinacidil (Lilly) and diazoxide (Shiseido and Schering-Plough) are known for their hair gro wth stimulating activity. Thus, U.S. Pat. Nos. 4,596,812 and 4,139,619 disclose use of minoxidil in the treatment of male pattern baldness, alopecia areata and balding in females. U.S. Pat. No. 4,057,636 discloses pinacidil. DE 3,827,467A discloses combinations of minoxidil and hydrocortisone or retinoids.
U.S. Pat. No. 5,011,837 to Atwal et al discloses aryl cyanoguanidines which possess potassium channel activating activity and are useful therapy for hypertension and other cardiovascular disorders, for various central nervous system disorders, kidney and urinary problems as well as for the promotion of hair growth, for example in the treatment of male pattern baldness (alopecia). These aryl cyanoguanidines have the structure ##STR1## and its possible tautomers ##STR2## including pharmaceutically acceptable salts, wherein ...."